Because cancer cells could develop resistance to inhibitors of protein translation and this class of drugs may not directly cause tumor cell death (Rozengurt et al., 2014; Zheng and Jiang, 2015), identifying other regimens which synergize with mTOR inhibitors is warranted. Here, MTOR is linked to neoplasm.